×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DTIL – precision biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DTIL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/18
07:08 am
dtil
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B [Yahoo! Finance]
High
Report
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B [Yahoo! Finance]
12/18
07:01 am
dtil
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
High
Report
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
11/29
04:47 am
dtil
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More [Yahoo! Finance]
Medium
Report
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More [Yahoo! Finance]
11/21
07:11 am
dtil
Precision BioSciences to Participate in Upcoming November Investor Conferences [Yahoo! Finance]
High
Report
Precision BioSciences to Participate in Upcoming November Investor Conferences [Yahoo! Finance]
11/21
07:01 am
dtil
Precision BioSciences to Participate in Upcoming November Investor Conferences
High
Report
Precision BioSciences to Participate in Upcoming November Investor Conferences
11/15
07:08 am
dtil
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B [Yahoo! Finance]
Medium
Report
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B [Yahoo! Finance]
11/15
07:00 am
dtil
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Medium
Report
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
11/4
07:20 am
dtil
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2024
07:01 am
dtil
precision biosciences, inc.
MISS
Report
-8.1%
precision biosciences, inc.
8/1/2024
07:15 am
dtil
precision biosciences, inc.
BEAT
Report
0.6%
precision biosciences, inc.
5/13/2024
07:00 am
dtil
precision biosciences, inc.
BEAT
Report
3.5%
precision biosciences, inc.
3/27/2024
06:45 am
dtil
precision biosciences, inc.
MISS
Report
-3.5%
precision biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:30 pm
dtil
Form 4 PRECISION BIOSCIENCES For: Nov 21 Filed by: Kelly John Alexander
Medium
Report
Form 4 PRECISION BIOSCIENCES For: Nov 21 Filed by: Kelly John Alexander
11/14
04:51 pm
dtil
Form SC 13G/A PRECISION BIOSCIENCES Filed by: PERCEPTIVE ADVISORS LLC
Low
Report
Form SC 13G/A PRECISION BIOSCIENCES Filed by: PERCEPTIVE ADVISORS LLC
11/14
04:01 pm
dtil
Form SC 13G/A PRECISION BIOSCIENCES Filed by: TANG CAPITAL MANAGEMENT LLC
Low
Report
Form SC 13G/A PRECISION BIOSCIENCES Filed by: TANG CAPITAL MANAGEMENT LLC
11/14
01:35 pm
dtil
Form SC 13G/A PRECISION BIOSCIENCES Filed by: JANUS HENDERSON GROUP PLC
Medium
Report
Form SC 13G/A PRECISION BIOSCIENCES Filed by: JANUS HENDERSON GROUP PLC
11/14
11:00 am
dtil
Form SC 13G PRECISION BIOSCIENCES Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Medium
Report
Form SC 13G PRECISION BIOSCIENCES Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
11/5
07:15 pm
dtil
Form 4 PRECISION BIOSCIENCES For: Nov 02 Filed by: Kelly John Alexander
Low
Report
Form 4 PRECISION BIOSCIENCES For: Nov 02 Filed by: Kelly John Alexander
11/5
07:14 pm
dtil
Form 4 PRECISION BIOSCIENCES For: Nov 02 Filed by: Amoroso Michael
Low
Report
Form 4 PRECISION BIOSCIENCES For: Nov 02 Filed by: Amoroso Michael
11/5
07:14 pm
dtil
Form 4 PRECISION BIOSCIENCES For: Nov 02 Filed by: Scimeca Dario
Low
Report
Form 4 PRECISION BIOSCIENCES For: Nov 02 Filed by: Scimeca Dario
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
Precision BioSciences Inc (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
24.6%
4/6 Form 8-K PRECISION BIOSCIENCES For: Apr 06 21.4%
11/6 Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting 18.6%
1/8 Form 4 PRECISION BIOSCIENCES For: Jan 06 Filed by: ANSARI ABID 17.3%
3/12 Form 3 PRECISION BIOSCIENCES For: Mar 10 Filed by: Germano Geno J 13.8%
4/28 Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting 6.8%
4/8 Precision BioSciences Inc (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock. 6.4%
11/12 Form 10-Q PRECISION BIOSCIENCES For: Sep 30 5.7%
2/24 Precision BioSciences: Consider Taking Up A Small Position [Seeking Alpha] 5.4%
11/13 Form 3 PRECISION BIOSCIENCES For: Nov 08 Filed by: Buehler Kevin 5.3%
4/6 Form 8-K PRECISION BIOSCIENCES For: Apr 06 21.4%
11/6 Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting 18.6%
1/8 Form 4 PRECISION BIOSCIENCES For: Jan 06 Filed by: ANSARI ABID 17.3%
3/12 Form 3 PRECISION BIOSCIENCES For: Mar 10 Filed by: Germano Geno J 13.8%
4/28 Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting 6.8%
4/8 Precision BioSciences Inc (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock. 6.4%
11/12 Form 10-Q PRECISION BIOSCIENCES For: Sep 30 5.7%
2/24 Precision BioSciences: Consider Taking Up A Small Position [Seeking Alpha] 5.4%
11/13 Form 3 PRECISION BIOSCIENCES For: Nov 08 Filed by: Buehler Kevin 5.3%
TOP News Decliners
12/9
Precision BioSciences stock rises on early-stage CAR-T trial data [MarketWatch]
-54.5%
3/12 Form 8-K PRECISION BIOSCIENCES For: Mar 12 -16.5%
4/15 Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources -16.4%
8/9 Precision BioSciences Inc (NASDAQ: DTIL) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock. -16.3%
4/2 Precision BioSciences Inc (NASDAQ: DTIL) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. -15.9%
3/11 Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano -14.6%
1/15 Form 8-K/A PRECISION BIOSCIENCES For: Jan 15 -12.4%
1/13 Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma -8.0%
9/25 Form 4 PRECISION BIOSCIENCES For: Sep 23 Filed by: KANE MATTHEW R. -7.7%
2/7 Form SC 13G PRECISION BIOSCIENCES Filed by: BlackRock Inc. -7.1%
3/12 Form 8-K PRECISION BIOSCIENCES For: Mar 12 -16.5%
4/15 Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources -16.4%
8/9 Precision BioSciences Inc (NASDAQ: DTIL) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock. -16.3%
4/2 Precision BioSciences Inc (NASDAQ: DTIL) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. -15.9%
3/11 Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano -14.6%
1/15 Form 8-K/A PRECISION BIOSCIENCES For: Jan 15 -12.4%
1/13 Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma -8.0%
9/25 Form 4 PRECISION BIOSCIENCES For: Sep 23 Filed by: KANE MATTHEW R. -7.7%
2/7 Form SC 13G PRECISION BIOSCIENCES Filed by: BlackRock Inc. -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: